

MAP Pharmaceuticals, Inc.
 Form 3
 October 04, 2007

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Bay City Capital Fund IV, L.P.			(Month/Day/Year)	MAP Pharmaceuticals, Inc. [MAPP]	
(Last)	(First)	(Middle)		4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
C/O BAY CITY CAPITAL,Â 750 BATTERY STREET, SUITE 400				(Check all applicable)	
(Street)				___ Director ___X___ 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
				___ Officer ___ Other	_X_ Form filed by One Reporting Person
				(give title below) (specify below)	___ Form filed by More than One Reporting Person
SAN FRANCISCO,Â CAÂ 94111					
(City)	(State)	(Zip)			

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	---	---	---

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Series B Preferred Stock ⁽¹⁾	10/10/2007 ⁽²⁾	10/10/2007 ⁽³⁾	Common Stock	1,091,815 ⁽⁴⁾	\$ 0 ⁽⁵⁾	I	See footnote ⁽⁶⁾
Series C Preferred Stock ⁽¹⁾	10/10/2007 ⁽²⁾	10/10/2007 ⁽³⁾	Common Stock	448,963 ⁽⁴⁾	\$ 0 ⁽⁵⁾	I	See footnote ⁽⁷⁾
Series D Preferred Stock ⁽¹⁾	10/10/2007 ⁽²⁾	10/10/2007 ⁽³⁾	Common Stock	629,829 ⁽⁴⁾	\$ 0 ⁽⁵⁾	I	See footnote ⁽⁸⁾

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Bay City Capital Fund IV, L.P. C/O BAY CITY CAPITAL 750 BATTERY STREET, SUITE 400 SAN FRANCISCO, CA 94111	Â	Â X	Â	Â

Signatures

/s/ Bay City Capital Fund IV, L.P. 10/04/2007

^{*}Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Automatically Convertible into shares of Common Stock upon the closing of the MAP Pharmaceuticals, Inc. Initial Public Offering.
- (2) Immediately Convertible.
- (3) Not Applicable.
- (4) Reflects 1-for-1 conversion into shares of Common Stock.
- (5) 1-for-1
- (6) Represents 1,068,779 shares held by Bay City Capital Fund IV, L.P. and 23,036 shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. Dr. Goldfischer is a Managing Director of Bay City Capital, an affiliate of Bay City Capital Fund IV, L.P. and Bay City Capital Fund IV Co-Investment Fund, L.P. and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- (7) Represents 439,490 shares held by Bay City Capital Fund IV, L.P. and 9,473 shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. Dr. Goldfischer is a Managing Director of Bay City Capital, an affiliate of Bay City Capital Fund IV, L.P. and Bay City Capital Fund IV Co-Investment Fund, L.P. and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- (8) Represents 616,540 shares held by Bay City Capital Fund IV, L.P. and 13,289 shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. Dr. Goldfischer is a Managing Director of Bay City Capital, an affiliate of Bay City Capital Fund IV, L.P. and Bay City Capital Fund IV Co-Investment Fund, L.P. and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.